KalVista Pharmaceuticals (KALV) News Today $8.96 -0.09 (-0.99%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 8,077 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.November 20 at 4:07 AM | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.November 20 at 4:06 AM | marketbeat.comFirst Turn Management LLC Sells 704,540 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)First Turn Management LLC trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 66.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 355,000 shares of the specialty pharmaceuNovember 19 at 6:08 AM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Passes Below Fifty Day Moving Average - Here's WhyKalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving Average - Here's What HappenedNovember 19 at 5:15 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)November 13, 2024 | markets.businessinsider.comLeerink Partnrs Analysts Boost Earnings Estimates for KALVKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings estimates for KalVista Pharmaceuticals in a report released on Monday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceuticaNovember 7, 2024 | marketbeat.comKalVista prices $55M stock offeringNovember 5, 2024 | msn.comKalVista Pharmaceuticals Announces $60 Million Funding InitiativesNovember 5, 2024 | markets.businessinsider.comKalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy RatingNovember 5, 2024 | markets.businessinsider.comKalVista Secures $184M Financing for Sebetralstat LaunchNovember 5, 2024 | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - What's Next?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Still a Buy?November 4, 2024 | marketbeat.comKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNovember 4, 2024 | businesswire.comEmerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Emerald Advisers LLC grew its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 29.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 835,988 shares of the specialty pharmaceutical company's stock after puNovember 3, 2024 | marketbeat.comKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyOctober 28, 2024 | businesswire.comKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)October 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest UpdateKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 6,510,000 shares, a growth of 13.8% from the September 15th total of 5,720,000 shares. Based on an average daily volume of 381,900 shares, the short-interest ratio is presently 17.0 days.October 16, 2024 | marketbeat.comAlnylam Pharma (ALNY) Receives a Buy from JefferiesOctober 11, 2024 | markets.businessinsider.comMarshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Marshall Wace LLP lowered its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 92.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,911 shares of the specialty pharmaceutical company's sOctober 10, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP trimmed its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 7.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 534,979 shares of the specialty pharmaceutical company's stock after selling 44,680 shaOctober 9, 2024 | marketbeat.comBuy Rating for KalVista Pharmaceuticals Based on Sebetralstat’s Market Potential and Patient Quality of Life ImprovementOctober 7, 2024 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday.October 7, 2024 | marketbeat.comKalVista Pharmaceuticals announces board election resultsOctober 6, 2024 | uk.investing.comKalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumOctober 4, 2024 | finance.yahoo.comSusquehanna Fundamental Investments LLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Susquehanna Fundamental Investments LLC increased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 323.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,526 shares of the specialty pharmaceuticaOctober 3, 2024 | marketbeat.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | businesswire.comKalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary AngioedemaSeptember 30, 2024 | businesswire.comJones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy RecommendationSeptember 28, 2024 | msn.comKalVista Pharma (NASDAQ:KALV) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comBuy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market PotentialSeptember 28, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)September 26, 2024 | businesswire.comGreat Point Partners LLC Invests $15.77 Million in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Great Point Partners LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,338,568 shares of the specialty pharmaceutical compSeptember 24, 2024 | marketbeat.comFirst Turn Management LLC Sells 119,880 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)First Turn Management LLC trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,059,540 shares of the specialty pharmaceuticaSeptember 13, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,352 SharesSeptember 12, 2024 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $89,620.88 in StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,352 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the transaction, the chief executive officer now owns 250,800 shares in the company, valued at approximately $3,057,252. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.September 10, 2024 | marketbeat.comKalVista Pharmaceuticals Names Brian Piekos Chief Financial OfficerSeptember 10, 2024 | marketwatch.comKalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | finance.yahoo.comMispro Announces Tenth Boston Location in Cambridge, MASeptember 9, 2024 | tmcnet.comKalVista Pharmaceuticals (NASDAQ:KALV) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday.September 9, 2024 | marketbeat.comResearch Analysts Offer Predictions for KalVista Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:KALV)KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued on Thursday, September 5th. Leerink Partnrs analyst J. Schwartz forecasts thaSeptember 9, 2024 | marketbeat.comKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024September 6, 2024 | finance.yahoo.comBuy Rating for KalVista Pharmaceuticals Amid Positive Regulatory Developments and Strong Financial PositionSeptember 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Prospects for Lead Drug Candidate, SebetralstatSeptember 6, 2024 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Issues Earnings ResultsKalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.04.September 6, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday.September 6, 2024 | marketbeat.comKalVista Pharmaceuticals: Looking To Be A Major Player In HAESeptember 5, 2024 | seekingalpha.comKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaSeptember 3, 2024 | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 9.3%KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 9.3%September 3, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to Post FY2025 Earnings of ($3.44) Per Share, Cantor Fitzgerald ForecastsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report issued on Monday, August 26th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the specialty pharmaceutical compaAugust 28, 2024 | marketbeat.comPaul K. Audhya Sells 2,135 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockAugust 28, 2024 | insidertrades.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Upgraded by Cantor FitzgeraldCantor Fitzgerald upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a report on Monday.August 27, 2024 | marketbeat.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.320.46▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼63▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALIM News ABUS News BYSI News BCRX News ARVN News KNSA News NTLA News SYRE News OCUL News DAWN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts